Table 1.

Prevalence and attribution of HPV types in CIN 1 and CIN 2/3 lesions

YearFirst authornMultitype infections (%)Percentage of specimens testing positive for individual HPV types
Any HPV type*
6111618313335394551525658596668707382
CIN 1 (41, 42, 45-47, 49, 53, 55)
2007Kong110.09.10.027.30.018.29.19.10.09.10.00.00.00.00.00.00.00.090.9
2007Guo234.90.00.09.99.90.05.89.94.959.3
2006Srodon360.02.82.811.116.75.65.68.32.85.62.82.80.02.82.811.15.60.0100.0
2005Hu458.98.92.26.70.02.22.213.311.187.0
2002Evans283.67.13.67.13.67.13.63.610.73.610.77.13.60.00.010.70.0100.0
1998Aoyama110.00.027.39.19.19.154.5
1998Quade300.03.33.310.03.36.70.00.00.00.00.00.010.00.00.00.00.00.00.073.3
1996Isacson405.010.0
Pooled prevalence2241.24.54.510.35.47.84.03.52.13.75.76.53.84.11.06.71.90.00.084.1
95% CI, lower2.22.26.73.04.72.01.60.81.72.63.71.52.00.23.30.50.00.0
95% CI, upper9.09.015.69.712.57.87.45.77.611.911.29.48.25.213.16.74.811.4
Multitype adjusted§1734.02.98.64.96.43.33.52.33.75.76.23.82.41.06.71.90.00.0
95% CI, lower1.71.05.32.53.61.51.60.71.72.63.51.51.00.23.30.50.00.0
95% CI, upper9.37.713.79.211.17.17.47.37.611.910.89.46.05.213.16.74.811.4
CIN 2/3(41, 42, 45-47, 49, 53, 55)
2007Kong1414.30.00.042.90.028.614.37.10.00.00.00.00.00.00.00.00.07.192.9
2007Guo6010.036.90.08.45.08.40.05.05.072.1
2006Srodon1160.00.00.075.04.35.21.75.20.00.00.00.90.93.40.90.90.00.0100.0
2005Hu9714.440.212.413.41.03.12.18.26.293.6
2002Evans220.00.00.068.24.59.14.50.00.04.50.00.04.54.50.00.00.0100.0
1998Aoyama210.00.052.40.019.019.095.2
1998Quade190.00.00.052.65.30.015.80.00.00.00.00.00.00.00.00.00.00.00.078.9
1996Isacson110.00.00.045.50.018.29.19.10.00.00.00.00.00.00.09.10.0100.0
Pooled prevalence3606.50.00.054.25.310.04.74.70.00.90.03.51.14.10.51.10.00.70.092.0
95% CI, lower0.00.049.03.47.33.03.00.00.30.02.10.32.40.10.30.00.10.0
95% CI, upper1.91.959.38.113.57.47.42.12.52.16.03.97.23.03.92.13.716.8
Multitype adjusted§3390.00.053.84.88.13.03.90.00.60.02.41.12.80.51.10.00.00.0
95% CI, lower0.00.048.53.05.72.02.30.00.20.01.20.31.40.10.30.00.00.0
95% CI, upper2.12.159.07.611.56.16.52.22.12.24.63.95.53.03.92.12.516.8
  • * As determined by consensus PCR primers sensitive to positivity for at least 15 HPV types.

  • In the Guo et al. study, 4 CIN 1 lesions and 1 CIN 2 lesion that tested HPV positive based on consensus primers were not further tested for specific HPV types due to insufficient DNA. Results from the analysis have been adjusted to reflect this.

  • n refers to total number of lesions with any HPV typing data. By individual HPV type, number of observations varies depending on the number of types for which data were available within each study.

  • § Lesions in these studies containing multiple HPV types were fractionally attributed to individual HPV types as described in Materials and Methods. Based on this method, figures for the attribution of individual HPV types differing from those reported in the table for prevalence were as follows: Evans et al. CIN 1 (HPV 6, 4.5%); Guo et al. CIN 1 (HPV 31, 7.4%; HPV 33, 7.4%; HPV 58, 0.0%), CIN 2/3 (HPV 16, 36.2%; HPV 31, 3.9%; HPV 33, 3.4%; HPV 52, 3.5%; HPV 58, 3.4%); Hu et al. CIN 1 (HPV 16, 6.4%; HPV 31, 3.1%; HPV 52, 12.2%; HPV 58, 7.2%), CIN 2/3 (HPV 16, 38.9%; HPV 18, 9.6%; HPV 31, 11.6%; HPV 35, 1.2%; HPV 45, 1.1%; HPV 52, 5.0%; HPV 58, 2.6%); Kong et al. CIN 2/3 (HPV 35; 0.0%, HPV 70, 0.0%).